


**Listing of Claims:**

Please cancel claims 1-28 and 39-77.

1-28. (Canceled)

29. (Original) A method of treating a metabolic bone disease where it is desired to maintain or increase bone mass comprising administering to a patient with said disease an effective amount of (20S)-1 $\alpha$ -hydroxy-2 $\alpha$ -methyl-19-nor-vitamin D<sub>3</sub> having the formula:



30. (Original) The method of claim 29 wherein (20S)-1 $\alpha$ -hydroxy-2 $\alpha$ -methyl-19-nor-vitamin D<sub>3</sub> is administered orally.

31. (Original) The method of claim 29 wherein (20S)-1 $\alpha$ -hydroxy-2 $\alpha$ -methyl-19-nor-vitamin D<sub>3</sub> is administered parenterally.

32. (Original) The method of claim 29 wherein (20S)-1 $\alpha$ -hydroxy-2 $\alpha$ -methyl-19-nor-vitamin D<sub>3</sub> is administered transdermally.

33. (Original) The method of claim 29 wherein (20S)-1 $\alpha$ -hydroxy-2 $\alpha$ -methyl-19-nor-vitamin D<sub>3</sub> is administered in a dosage of from about 0.01  $\mu$ g/day to about 100  $\mu$ g/day.

34. (Original) The method of claim 29 wherein the disease is senile osteoporosis.

35. (Original) The method of claim 29 wherein the disease is postmenopausal osteoporosis.

Applicants: Hector F. DeLuca et al  
Attorney Docket 1256-00943

36. (Original) The method of claim 29 wherein the disease is steroid-induced osteoporosis.

37. (Original) The method of claim 29 wherein the disease is low bone turnover osteoporosis.

38. (Original) The method of claim 29 wherein the disease is osteomalacia.

39-77. (Canceled)